Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Total Current Liabilities (2016 - 2025)

Haemonetics has reported Total Current Liabilities over the past 16 years, most recently at $539.9 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 113.19% year-over-year to $539.9 million; the TTM value through Dec 2025 reached $539.9 million, up 113.19%, while the annual FY2025 figure was $578.1 million, 92.46% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $539.9 million at Haemonetics, down from $548.3 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $578.1 million in Q1 2025 and troughed at $180.5 million in Q3 2022.
  • A 5-year average of $326.9 million and a median of $263.2 million in 2022 define the central range for Total Current Liabilities.
  • Biggest five-year swings in Total Current Liabilities: crashed 44.01% in 2021 and later skyrocketed 113.19% in 2025.
  • Year by year, Total Current Liabilities stood at $288.5 million in 2021, then fell by 21.35% to $226.9 million in 2022, then increased by 15.37% to $261.8 million in 2023, then dropped by 3.26% to $253.2 million in 2024, then skyrocketed by 113.19% to $539.9 million in 2025.
  • Business Quant data shows Total Current Liabilities for HAE at $539.9 million in Q4 2025, $548.3 million in Q3 2025, and $531.4 million in Q2 2025.